|
|
 |
|
Viewing report
|
|
|
|
Bristol-Myers Squibb: Pipeline - Products - Performance - Potential
Espicom Business Intelligence Ltd, Feb 2009, Pages: 144
Bristol-Myers Squibb (BMS) is a research-based, worldwide pharmaceutical and related health care products company. BMS was founded in 1989, and currently operates through three main business divisions: Pharmaceuticals, Nutritionals and Other Health Care. Within Pharmaceuticals, BMS’ key areas of interest are cardiovascular and metabolic disorders, virology, oncology, neuroscience and immunology.
Since the merger to form the company in 1989, BMS has consistently been in the top ten research-based pharmaceutical companies in terms of pharmaceutical sales. However, in 2006, BMS reported its third consecutive year of revenue loss, which looked to threaten this position. The company is going through a transitional period, whereby many older products have seen considerable declines in sales due to generic competition whilst newer products begin to establish themselves in the market place. In fiscal 2007, BMS once again returned to revenue growth.
BMS’ is looking to refresh its product portfolio, adopting a strategy of increased R&D investment despite decreased income. To this end, BMS’ research to sales ratio has increased from 12.2 per cent in 2003, to 17.4 per cent in 2008. Higher levels of expenditure have reaped dividends for the company with five new products launched between 2005 and 2006. Orencia, Sprycel, Emsam, Atripla and Baraclude signify the first stages of BMS’ new direction and profile.
There are also several established products in the portfolio which will help drive BMS’ pharmaceutical sales in the future. Avapro continues to benefit from co-development and co-marketing with sanofi-aventis and, along with Plavix, is the main focus of their collaboration. BMS is a world leader in virology, with the Sustiva franchise (which now includes Atripla) and Reyataz forecast to be leading competitors in this field for some time. The company is also heavily involved in projects to provide HIV/AIDS treatment on a worldwide scale, most notably in sub-Saharan Africa where there is the highest level of unmet medical need. Within neuroscience, Abilify continues to sell well, whilst in oncology, Erbitux has been launched and is being investigated in a variety of oncology conditions. This versatility should ensure strong sales growth.
This new strategic analysis report Bristol-Myers Squibb: Pipeline, Products, Performance, Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.
Customers who bought this item also bought
Bristol-Myers Squibb Co.: PharmaVitae Profile
Bristol-Myers Squibb Company - SWOT Analysis
Company Report: Bristol-Myers Squibb
PharmaVitae 2003: Bristol-Myers Squibb
Bristol-Myers Squibb: Pharmavitae Profile
Bristol-Myers Squibb Company
Pharmavitae 2005: Bristol-Myers Squibb Global Analysis
PharmaVitae 2002: Bristol-Myers Squibb
Bristol-Myers Squibb Company - Strategic Analysis Review
Company Analysis - Bristol-Myers Squibb Co.
Analysis of Bristol Myers Squibb
PharmaVitae 2004: Bristol-Myers Squibb Global Analysis
|
|
|
|
